$TER

Smith Gregory Stephen sold $1.4M of TER

Smith Gregory Stephen (President and CEO) sold 4,000 shares of TERADYNE, INC (TER) at $337.83 ($1.35M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Smith Gregory Stephen
Published Sep 16, 2026, 4:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 4:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TER
Bearish
medium confidence
Mentioned
$TER
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TERBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership, which may be interpreted as a negative signal, but the pre-arranged 10b5-1 plan tempers speculation.

02

Market read

The filing provides fresh insider activity data, offering a modest trading cue for TER.

03

What to watch

Potential upcoming earnings or strategic announcements could contextualize the sale.

Relevance 5/10Novelty 7/10Timing: post-market 2026-09-15

Background

Form 4 filings disclose insider transactions; a CEO sale often draws investor attention.

Company-level read

Ticker impact

$TERBearishMedium confidence
Context

CEO Stephen Smith sold 4,000 shares for $1.35M via a 10b5-1 plan, reducing his stake to 108,495 shares.

Expected impact

Possible modest downside pressure in the near term.

Evidence & confidence

The sale size is material for a mid-cap and executed under a pre-arranged plan, suggesting a neutral to slightly negative market reaction.

Market effects

Minimal impact on the broader medical device sector.

Limited to U.S. investors tracking insider activity.

Low

Counterpoint

The sale may be purely liquidity-driven, not indicative of company outlook.

Key entities

  • Stephen Smith

    President and CEO of Teradyne, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TERMed

Teradyne Partners With GS Microelectronics On New Semiconductor Test Center — Targets AI, Silicon Photonics And Auto Chips

Teradyne (TER) and GS Microelectronics U.S. (GSME) announced a multi-year partnership to establish a test-and-evaluation center for AI and next-generation chips. The facility, set to open in Q4 2026, will combine GSME's chip design and manufacturing with Teradyne's test systems. Teradyne's Semiconductor Test segment reported record Q2 revenue of $1.12 billion, up 128.1% YoY, driven by AI-related sales. Overall Q2 revenue was $1.33 billion, up 104% YoY. TER shares have risen nearly 90% YTD.

$FORMMedAI 8/10

FormFactor, Entegris, Penguin Solutions, Teradyne, and Marvell Technology Stocks Trade Up, What You Need To Know

Several semiconductor stocks rose after the August jobs report, which showed 162,000 nonfarm payroll jobs added, beating estimates. Despite initial expectations of a rate hike, traders rotated back into the chip sector. FormFactor (FORM) +5.3%, Entegris (ENTG) +5.6%, Penguin Solutions (PENG) +5.1%, Teradyne (TER) +4.8%, and Marvell Technology (MRVL) +6.2%. Marvell reported Q2 revenue of $2.74B, up 36.5% YoY, with strong Data Center demand. Management guided Q3 revenue at $3.15B, but revenue from

$TERMed

Teradyne Stock Plunges 15% in a Month: Should You Buy the Dip?

Teradyne (TER) shares fell 15.4% in a month, underperforming peers and sector. Challenges include customer concentration and muted demand, but AI-driven data center growth and strong Q3 guidance offset this. TER expects $1.20-$1.30B revenue and $1.85-$2.15 EPS for Q3 2026, up significantly YoY. The stock trades at a premium with a forward P/S of 9.35X.